Search Results



Your search for The ASCO Post matches 6678 pages

Showing 151 - 200


leukemia

Novel Risk-Assessment Model for Acute Myeloid Leukemia

A RECENTLY PUBLISHED STUDY in JAMA Oncology, led by Mohamed Sorror, MD, MSc, and Elihu Estey, MD, of the Fred Hutchinson Cancer Research Center (Fred Hutch), involving five collaborating institutions, provides a novel model to predict 1-year survival rates of patients after beginning treatment...

solid tumors

Early Findings on EZH2 Inhibitor in Children With Rare Solid Tumors

CHILDREN WITH relapsed or refractory malignant rhabdoid tumors, epithelioid sarcomas, or poorly differentiated chordomas with a particular genetic defect were treated with the investigational drug tazemetostat and appeared to tolerate treatment well. Some patients had objective and durable...

Moffitt Researcher Awarded Grant to Study New Treatments for Triple-Negative Breast Cancer

MOFFITT CANCER CENTER recently announced that Andriy Marusyk, PhD, was awarded a $450,000 research grant from Susan G. Komen. Dr. Marusyk is receiving 1 of 37 research grants looking into novel treatments for aggressive types of breast cancer. This year, Susan G. Komen is focusing on new...

genomics/genetics
solid tumors
lymphoma
multiple myeloma

Update on NCI-MATCH Precision Medicine Trial

THE NATIONAL CANCER INSTITUTE (NCI) Molecular Analysis for Therapy Choice (MATCH) clinical trial has achieved the goal of screening nearly 6,000 patients in just under 2 years, according to data presented at the 2017 American Association for Cancer Research–NCI–European Organisation for Research...

hematologic malignancies

A Pioneer in Bloodless Transplant Discusses Advances in Blood Management

Bloodless stem cell transplantation, performed without the transfusion of allogeneic blood or blood products, has numerous clinical advantages, especially among populations of patients who prefer, for religious or other reasons, no blood methods of medical and surgical treatment. Patricia A. Ford, ...

Angela M. Stover, PhD, Presented With Inaugural Michael S. O’Malley Alumni Award

ANGELA M. STOVER, PhD, Assistant Professor in Health Policy and Management at the University of North Carolina (UNC) Gillings School of Global Public Health, has won the 2017 Michael S. O’Malley Alumni Award for Publication in Excellence in Cancer Population Sciences. She was selected for her...

Arif Kamal, MD, MBA, MHS, Named Visionary in Hospice and Palliative Medicine

ARIF KAMAL, MD, MBA, MHS, Associate Professor of Medicine and Business Administration and Physician Director of Quality at the Duke Cancer Institute, was recently named by the American Academy of Hospice and Palliative Medicine as 1 of the 30 most influential leaders in hospice and palliative...

lymphoma

FDA Approves CAR T-Cell Therapy for Adults With Certain Types of Large B-Cell Lymphoma

ON OCTOBER 18, the U.S. Food and Drug Administration (FDA) approved axicabtagene ciloleucel (Yescarta), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment....

West Cancer Center Joins CancerLinQ® as Participating Practice

CANCERLINQ LLC, a wholly owned nonprofit subsidiary of ASCO, has announced that West Cancer Center in Tennessee has signed an agreement to participate in the CancerLinQ® platform.  “The CancerLinQ® rapid learning system continues to be enriched through the participation of remarkable cancer care...

lung cancer

ESMO Asia 2017: FLAURA Trial: Osimertinib Improves Progression-Free Survival in Asian Patients With EGFR-Mutated NSCLC

Osimertinib (Tagrisso) improves progression-free survival compared to standard first-line therapy in Asian patients with EGFR-mutated non–small cell lung cancer (NSCLC), according to the Asian subset analysis of the FLAURA trial presented at the European Society for Medical Oncology (ESMO)...

colorectal cancer

ESMO Asia 2017: AXEPT Trial: New Second-Line Therapy for Metastatic Colorectal Cancer Is Effective and Safe

A randomized trial in 650 patients has confirmed the safety and efficacy of a new second-line treatment for metastatic colorectal cancer, researchers reported at the European Society for Medical Oncology (ESMO) Asia 2017 Congress (Abstract LBA3_PR). Oral fluorinated pyrimidines have been...

Stand Up To Cancer Launches ‘Cancer Interception’ Teams to Detect and Treat Cancer at Earliest Stages

Stand Up To Cancer, joined by the Lustgarten Foundation for Pancreatic Cancer Research, LUNGevity, and the American Lung Association, announced that four teams of top researchers will study lung and pancreatic cancers using a new approach of “cancer interception” at their earliest stages. “The...

lung cancer

ESMO Asia 2017: Analysis of Mutations in Cerebrospinal Fluid in Lung Cancer With Brain Metastases

In a study presented at the European Society for Medical Oncology (ESMO) Asia 2017 Congress (Abstract 35P_PR), researchers analyzed the presence of mutations in the cerebrospinal fluid of patients with lung cancer and brain metastases. Tumor tissue from brain metastasis is difficult to obtain,...

NCCN Hits 1 Million Registered Users Accessing NCCN Guidelines® and Related Content

The National Comprehensive Cancer Network® (NCCN®) has announced that its registration count has grown to more than 1 million users. By registering on the NCCN website, users are able to view and download all of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) free of charge...

gynecologic cancers

PARP Inhibitors in BRCA-Related Ovarian Cancer—and Beyond!

Poly (ADP ribose) polymerase (PARP) inhibitors are among the most exciting new classes of oncology drugs, and their development has coincided with the increasing recognition of the therapeutic vulnerability in targeting DNA damage response and DNA repair. The initial clinical testing of PARP...

lung cancer

ESMO Asia 2017: Alectinib More Effective Than Crizotinib in Asian Patients With ALK-Positive NSCLC

A subanalysis of the phase III ALEX study has shown that alectinib (Alecensa) is more effective than the standard of care, crizotinib, in Asian patients with anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC), researchers reported at the European Society for Medical...

lymphoma

FDA Approves Obinutuzumab for Previously Untreated Advanced Follicular Lymphoma

On November 16, Genentech announced that the U.S. Food and Drug Administration (FDA) approved obinutuzumab (Gazyva) in combination with chemotherapy, followed by obinutuzumab alone in those who responded, for people with previously untreated advanced follicular lymphoma (stage II bulky, III, or...

kidney cancer

FDA Expands Approval of Sunitinib Malate for Adjuvant Treatment of Renal Cell Carcinoma After Nephrectomy

Today, the U.S. Food and Drug Administration (FDA) approved sunitinib malate (Sutent) for the adjuvant treatment of adult patients who are at a high risk of recurrent renal cell carcinoma after nephrectomy. “This is the first adjuvant treatment approved for patients with renal cell...

issues in oncology

FDA Announces Comprehensive Regenerative Medicine Policy Framework

On November 16, the U.S. Food and Drug Administration (FDA) announced a comprehensive policy framework for the development and oversight of regenerative medicine products, including novel cellular therapies. The framework—outlined in a suite of four guidance documents—builds upon the...

colorectal cancer
issues in oncology

Differences in Insurance Coverage Associated With Nearly Half of Black-White Survival Disparity in Colorectal Cancer

Health insurance coverage differences account for nearly one-half of the black-white survival disparity in colorectal cancer patients, according to a new study published by Sineshaw et al in Gastroenterology. The findings reinforce the importance of equitable health insurance coverage to mitigate...

ESMO Publishes Precision Medicine Glossary

The European Society for Medical Oncology (ESMO) has published its ESMO Precision Medicine Glossary in Annals of Oncology. The glossary’s 43 definitions are set to pave the way for consistent communication on precision medicine between oncologists, researchers, and patients by standardizing...

health-care policy
issues in oncology
legislation

Hospital Groups File Lawsuit to Stop Significant Payment Cuts for 340B Hospitals

The American Hospital Association (AHA), the Association of American Medical Colleges (AAMC), and America’s Essential Hospitals have filed a lawsuit against the U.S. Department of Health and Human Services (HHS) in the U.S. District Court for the District of Columbia to prevent significant...

breast cancer

FDA Approves Fulvestrant in Combination With Abemaciclib in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

Today, the U.S. Food and Drug Administration (FDA) approved a new indication for fulvestrant (Faslodex), expanding the drug's approved use to include combined therapy with abemaciclib (Verzenio), a cyclin-dependent kinase (CDK) 4/6 inhibitor, for the treatment of hormone receptor–positive,...

solid tumors

FDA Authorizes MSK-IMPACT Tumor Profiling Assay

Today, the U.S. Food and Drug Administration (FDA) authorized Memorial Sloan Kettering Cancer Center’s MSK-IMPACT tumor profiling assay, an in vitro diagnostic test that can identify more biomarkers that may be found in various cancers than any test previously reviewed by the...

colorectal cancer

Ventana MMR IHC Panel for Patients Diagnosed With Colorectal Cancer Receives FDA Clearance

On November 14, the U.S. Food & Drug Administration (FDA) granted clearance to the Ventana MMR IHC Panel, which provides clinicians with a comprehensive group of immunohistochemistry (IHC) tests for patients diagnosed with colorectal cancer. The tests detect proteins associated with the DNA...

prostate cancer

TMPRSS2-ERG Genetic Fusion May Be Associated With Low-Risk Prostate Cancer

Establishing the way in which a genetic alteration called a TMPRSS2-ERG gene fusion forms in a prostate cancer, rather than the presence of the gene fusion itself, could help identify patients with prostate cancer with a low risk of spreading, which might determine the best course of treatment for...

lung cancer

Chronic Stress Hormones May Promote Resistance to EGFR Inhibitors in Patients With Lung Cancer

Elevated levels of chronic stress hormones, such as those produced by psychological distress, may promote resistance to drugs commonly used to treat lung cancer patients with EGFR mutations, according to new research from The University of Texas MD Anderson Cancer Center. Retrospective analysis of...

Donald Coffey, PhD, Prostate Cancer Expert, Dies at 85

Donald Coffey, PhD, a distinguished Johns Hopkins professor and prostate cancer expert, who was the former Director of the Brady Urological Research Laboratory and Deputy Director of the Johns Hopkins Kimmel Cancer Center, died on November 9 at the age of 85. Long Career at Johns Hopkins In his...

leukemia

FDA Grants Regular Approval of Dasatinib for Pediatric Philadelphia Chromosome–Positive CML in Chronic Phase

On November 9, the U.S. Food and Drug Administration (FDA) expanded the indication for dasatinib (Sprycel) tablets to include the treatment of children with Philadelphia chromosome–positive chronic myeloid leukemia (CML) in chronic phase (CP).This approval for dasatinib in pediatric patients...

lymphoma

FDA Approves Brentuximab Vedotin for Primary Cutaneous Anaplastic Large Cell Lymphoma

Today, the U.S. Food and Drug Administration (FDA) granted regular approval to brentuximab vedotin (Adcetris) for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides who have received prior systemic therapy. ALCANZA...

hematologic malignancies

FDA Approves Letermovir for Prophylaxis of Cytomegalovirus Infection and Disease in Allogeneic Stem Cell Transplant Patients

Today, the U.S. Food and Drug Administration (FDA) approved letermovir (Prevymis) once-daily tablets for oral use and injection for intravenous infusion. Letermovir is indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogeneic...

gynecologic cancers

ARIEL3 Investigators Clarify the Effects of Rucaparib on the Liver

PRIMARY RESULTS from the randomized, placebo-controlled, phase III study ARIEL3—presented at the European Society for Medical Oncology (ESMO) 2017 Congress and published recently in The Lancet1—demonstrated that maintenance treatment with the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib ...

Life With Death in the Room

It began, as so many do, with what a doctor often calls “a small spot,” a vague description that makes a potentially fatal disease sound like something that, with a slight bit of attention, can be ridded, like erasing a misplaced comma. In 2015, during a routine mammogram, doctors found one “small ...

A Revolutionary Technology Offers Hope and Ethical Concern

Aldous Huxley’s classic 1932 dystopian novel Brave New World pictures an eerie future where humans are genetically bred, altered to create worthy citizens. Welcome back to the future. First there was the astounding feat of sequencing the entire human genome; now, thanks to a revolutionary...

breast cancer

Higher Risk of Breast Cancer Does Not Motivate Cancer Screening in Many Women

Some women, because of genetic predisposition, personal, or family history, have a higher-than-average lifetime risk of developing breast cancer. For those women, earlier magnetic resonance imaging (MRI) is recommended for cancer screening. But according to new findings presented at the American...

Gerold Bepler, MD, PhD, Elected to Association of American Cancer Institute’s Board of Directors

GEROLD BEPLER, MD, PhD, President and Chief Executive Officer of the Barbara Ann Karmanos Cancer Institute, has been elected to serve a 3-year term on the Association of American Cancer Institutes (AACI) Board of Directors. AACI comprises 97 leading cancer research centers in North America and is...

New Cancer Care Collaboration Brings Memorial Sloan Kettering Cancer Care to Norwalk Hospital

NORWALK HOSPITAL and Memorial Sloan Kettering Cancer Center (MSK) announced a new cancer care collaboration that will integrate MSK medical and radiation oncologists and care practices with the existing cancer program at the C. Anthony and Jean Whittingham Cancer Center at Norwalk Hospital.  For...

National Cancer Institute Awards Dr. Ruth Etzioni 5-Year Grant to Fill Gaps in Cancer-Recurrence Data

RUTH ETZIONI, PhD, a Biostatistician at Fred Hutchinson Cancer Research Center’s Public Health Sciences Division, has received a 5–year National Institutes of Health grant to advance the science of cancer surveillance by developing, validating, and deploying a scalable and automated approach for...

Two Individuals Recognized With NCCS Ellen L. Stovall Award

THE NATIONAL COALITION FOR CANCER SURVIVORSHIP (NCCS) presented its second annual Ellen L. Stovall Award for Innovation in Patient-Centered Cancer Care recently in Washington, DC. This year’s award recipients were Pat Coyne, MSN, of the Medical University of South Carolina, and Meg Gaines, JD, of...

Fox Chase Cancer Center Receives Historic Gift to Establish Pancreatic Cancer Institute

PHILADELPHIA PHILANTHROPIST Concetta “Chet” Greenberg has made a transformational gift to create The Marvin and Concetta Greenberg Pancreatic Cancer Institute at Fox Chase Cancer Center. This multimillion-dollar commitment will significantly accelerate the pace of pancreatic cancer research, and...

UCLA Researchers Awarded $1M Grant to Advance Prostate Cancer Research

UNIVERSITY OF CALIFORNIA at Los Angeles (UCLA) researchers Johannes Czernin, MD, and Caius Radu, MD, have been awarded a 2017 Challenge Award from the Prostate Cancer Foundation to fund their preclinical studies and clinical trials testing the efficacy of 177-Lu-PSMA-617, a novel radiation-emitting ...

symptom management

FDA Approves Intravenous Rolapitant for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting

ON OCTOBER 25, the U.S. Food and Drug Administration (FDA) approved intravenous (IV) rolapitant (Varubi) in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including...

skin cancer

Balancing Immune-Related Adverse Events With Efficacy of Dual Checkpoint Inhibitor Therapy in Melanoma

MUCH PROGRESS has been made in the past decade in the treatment of patients with newly diagnosed metastatic melanoma. In the front-line setting, programmed cell death protein 1 (PD-1) monotherapy (nivolumab [Opdivo] and pembrolizumab [Keytruda]) and combined PD-1 plus cytotoxic...

lung cancer

Long-Term Survival Rates More Than Double Previous Estimates for Locally Advanced Lung Cancer

THE LONG-TERM RESULTS of a phase III clinical trial indicate that survival rates for patients receiving chemoradiation for unresectable, locally advanced non–small cell lung cancer (NSCLC) may be more than twice as high as previous estimates, setting a new benchmark of survival for patients with...

lung cancer

Study Finds More Patients Treated for and Surviving Early-Stage NSCLC

WITH THE ADVANCEMENT of surgical and radiation therapy strategies for stage I non–small cell lung cancer (NSCLC), more patients are being treated, resulting in higher survival rates, according to a study published online in The Annals of Thoracic Surgery.1  “More and more patients are being cured...

lung cancer

Dacomitinib vs Gefitinib in Advanced NSCLC: Improving Upon Established First-Line Targeted Therapy

THE RESULTS FROM the ARCHER 1050 study—reported by Wu et al1 and reviewed in this issue of The ASCO Post—highlight the recent optimism about improved outcomes in metastatic non–small cell lung cancer (NSCLC) harboring mutations in the epidermal growth factor receptor (EGFR) gene. This trial...

New Editor-in-Chief Named to Annals of Surgical Oncology

THE SOCIETY OF SURGICAL ONCOLOGY has announced Kelly M. McMasters, MD, PhD, will assume the role of Editor-in-Chief of Annals of Surgical Oncology, effective March 2018. Dr. McMasters will oversee the print and online editions of the journal and, with Mark Roh, MD, Executive Editor, will lead the...

National Academy of Medicine Elects 80 New Members

THE NATIONAL ACADEMY OF MEDICINE announced the election of 70 regular members and 10 international members during its annual meeting in October. Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated...

issues in oncology

ASCO Cites Evidence That Alcohol Is Linked to Cancer, Calls for Reduced Alcohol Consumption

Alcohol use—whether light, moderate, or heavy—is linked with increasing the risk of several leading cancers, including those of the breast, colon, esophagus, and head and neck, according to evidence gathered by ASCO. In a statement released November 7 identifying alcohol as a definite...

pain management

Jenske Geerling, NP, on Painful Bone Metastases: Study Results on Nurse-Led Pain Education

Jenske Geerling, NP, of the University Medical Center Groningen, discusses findings from a multicenter trial on patient education, pain reduction, and quality of life (Abstract 203).

Advertisement



Advertisement


Advertisement